WO2009046872A3 - Use of a peptide as a therapeutic agent - Google Patents

Use of a peptide as a therapeutic agent Download PDF

Info

Publication number
WO2009046872A3
WO2009046872A3 PCT/EP2008/008137 EP2008008137W WO2009046872A3 WO 2009046872 A3 WO2009046872 A3 WO 2009046872A3 EP 2008008137 W EP2008008137 W EP 2008008137W WO 2009046872 A3 WO2009046872 A3 WO 2009046872A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
phe
asp
met
peptide
Prior art date
Application number
PCT/EP2008/008137
Other languages
French (fr)
Other versions
WO2009046872A2 (en
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Lab Ag
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Lab Ag, Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher filed Critical Mondobiotech Lab Ag
Publication of WO2009046872A2 publication Critical patent/WO2009046872A2/en
Publication of WO2009046872A3 publication Critical patent/WO2009046872A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the use of the combination of the His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2 and Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
PCT/EP2008/008137 2007-09-11 2008-09-09 Use of a peptide as a therapeutic agent WO2009046872A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017746.4 2007-09-11
EP07017745 2007-09-11
EP07017746 2007-09-11
EP07017745.6 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009046872A2 WO2009046872A2 (en) 2009-04-16
WO2009046872A3 true WO2009046872A3 (en) 2009-08-20

Family

ID=40262206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008137 WO2009046872A2 (en) 2007-09-11 2008-09-09 Use of a peptide as a therapeutic agent

Country Status (1)

Country Link
WO (1) WO2009046872A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016059191A1 (en) * 2014-10-16 2016-04-21 Academisch Medisch Centrum Nk3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175460A (en) * 1983-03-24 1984-10-04 Ajinomoto Co Inc Decapeptide
EP0892053A2 (en) * 1997-07-14 1999-01-20 Smithkline Beecham Plc production of recombinant HPMBQ91 polypeptide and uses thereof
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis
EP1745798A2 (en) * 1999-10-01 2007-01-24 Intercell AG Hcv vaccine compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175460A (en) * 1983-03-24 1984-10-04 Ajinomoto Co Inc Decapeptide
EP0892053A2 (en) * 1997-07-14 1999-01-20 Smithkline Beecham Plc production of recombinant HPMBQ91 polypeptide and uses thereof
EP1745798A2 (en) * 1999-10-01 2007-01-24 Intercell AG Hcv vaccine compositions
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANIL K MANTHA ET AL: "Membrane Associated Functions of Neurokinin B (NKB) on A[beta] (25-35) Induced Toxicity in Aging Rat Brain Synaptosomes", BIOGERONTOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 7, no. 1, 1 February 2006 (2006-02-01), pages 19 - 33, XP019230599, ISSN: 1573-6768 *
ANIL K MANTHA ET AL: "Neuroprotective Role of Neurokinin B (NKB) on [beta]-amyloid (25-35) Induced Toxicity in Aging Rat Brain Synaptosomes: Involvement in Oxidative Stress and Excitotoxicity", BIOGERONTOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 7, no. 1, 1 February 2006 (2006-02-01), pages 1 - 17, XP019230598, ISSN: 1573-6768 *
EISUKE ET AL: "Neurokinin A and B", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. C. COMPARATIVEPHARMACOLOGY, PERGAMON PRESS , OXFORD, GB, vol. 98, no. 1, 1 January 1991 (1991-01-01), pages 171 - 179, XP025945404, ISSN: 0306-4492, [retrieved on 19910101] *
SEVERINI C ET AL: "The Tachykinin Peptide Family", PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD, US, vol. 54, no. 2, 1 January 2002 (2002-01-01), pages 285 - 322, XP002981022, ISSN: 0031-6997 *
YANG ET AL: "Bimodal effects of chronically administered neurokinin B (NKB) on in vivo and in vitro cardiovascular responses in female rats", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 143, no. 1-3, 10 August 2007 (2007-08-10), pages 136 - 142, XP022192151, ISSN: 0167-0115 *

Also Published As

Publication number Publication date
WO2009046872A2 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
WO2009033821A3 (en) Use of a peptide as a therapeutic agent
WO2009043518A3 (en) Use of a combination of cart peptides as a therapeutic agent
WO2009043522A3 (en) Use of a peptide as a therapeutic agent
LTPA2017015I1 (en) Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases
EA201201400A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF AUTOIMMUNE AND OTHER DISEASES
HK1110526A1 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2009033819A3 (en) Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
WO2012061390A3 (en) Therapeutic compositions and methods
WO2010088527A3 (en) Peptides and nanoparticles for therapeutic and diagnostic applications
WO2009103959A3 (en) Histidine and/or histidine derivative for the treatment of inflammatory skin diseases
WO2009043525A3 (en) Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
WO2010094734A3 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2009033813A3 (en) Use of a peptide as a therapeutic agent
WO2009033818A3 (en) Use of a peptide as a therapeutic agent
WO2009033814A3 (en) Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
WO2009033820A3 (en) Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
WO2009046875A3 (en) Combination of splenopentin and thymopentin and the use thereof in medicine
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2008051421A3 (en) Peptide-cytotoxic conjugates
WO2009033809A3 (en) Use of a peptide as a therapeutic agent
WO2009043519A3 (en) Use of band 3 protein and pacap-27 as a therapeutic agent
WO2009046872A3 (en) Use of a peptide as a therapeutic agent
WO2008009426A9 (en) 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
WO2009043523A3 (en) Cortistatin 17 and neuropeptide 1 for use as therapeutic agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802606

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802606

Country of ref document: EP

Kind code of ref document: A2